González-Serrano B, Mendoza-Medellín LN, Castillo-Arriaga A

Language: Spanish
References: 30
Page: 82-87
PDF size: 168.12 Kb.

ABSTRACT

Introduction: Neurological damage is the common cause of physical disability in children with an incidence of 2 to 2.5 per 1000 live births, and has the highest demand for care at CRIT in Oaxaca. Botulinum toxin type A is an option for the treatment of spasticity, inhibiting the release of acetylcholine at the neuromuscular function. The objective of study to determine the degree of improvement in children with neurological damage in spastic hand functionality after application of botulinum toxin type A followed by an occupational therapy program.
Material and methods: Prospective longitudinal study with a sample of 21 patients with spastic cerebral lesions.
Results: The results show improvement after the application of botulium toxin type A and the proposed treatment program. 57.1% of the sample presented with apprehension-delayed grip, while 42.9% were able to grip at a normal rate. In relation to the R. Erhardt gripping component scale, after treatment 52.4% were able to perform a radio-digital grip, 36.1% were able to perform a radio-palmar grip, and 4.8% had a palmar grip equal to a cubital grip. Statistical analysis was performed using a paired t-test with a value of p = .000.
Discussion: The application of botulinum toxin type A in conjunction with an occupational therapy program enhances the functionality of hand spasticity in children with neurological damage.

REFERENCES

1. Reddihough DS, Collins KJ. The epidemiology and causes of cerebral palsy. Aust J Physiother 2003; 49: 7-12.

2. Rosenbaum P, Stewart D. The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice research in the field of cerebral palsy. Semin Pediatr Neurol 2004; 11: 5-10.

3. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Propose definition and classification of cerebral palsy. Dev Med Child Neurol 2005; 47: 571-6.

4. Surveillance of Cerebral Palsy in Europe (SCPE). Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002; 44: 633- 40.

5. Wichers MJ, Van der Schouw YT , Moons KG, Stam HJ, Van Ni euwe huizen O. Prevalence of cerebral palsy in The Netherlands (1977- 1988). Eur J Epidemi ol 2001; 17: 527-32.

6. Krigger KW. Cerebral palsy: an overview. Am Fam Physician 2006; 73: 91-100.

7. Cabañas F, Pellicer A. Lesión Cerebral en el niño prematuro. Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología. Asociación Española de Pediatría. Protocolos actualizados al año 2008; 253-258.

8. Coutiño L.B. Daño Neurológico Encefálico, por encefalopatía no progresiva. Última ed. Aguascalientes, México: Talleres de Servim presos del Centro S. A. De C. V; Octubre 2002.

9. Mutch L. Alberman, Hagberg B, Kodama K, Perat MV. Cerebral palsy epidemiology: where are we now and where are we going? Dev Med Child Neurol 1992; 34 (6): 547-551.

10. Federmann N. Neurología Pediátrica. El Ateneo 1988; 75-79.

11. Sheperd R. Fisioterapia en Pediatría. Salvat. Barcelona, España 1981; 51-105.

12. Robaina CG , Rodríguez RS, Robaina M. Evaluación diagnóstica del niño con parálisis cerebral. Rev Cubana de Pediatría 2007; 79: 147-149.

13. Vanerio J A. Tratami ento de la mano espástica. Rev Med Uruguay 1988; 4:173- 180.

14. Szabo R.M. Operative Treatment of cerebral palsy. Hand Clinic 1985; 1: 3.

15. Forssberg H. Tedroff K.B. Botulinum toxin reatment in cerebral palsy. Dev Med Child Neurol 1997; 39: 635-640.

16. Juárez S.G. Toxina botulínica: uso en medicina de rehabilitación, mitos y realidades. Rev Mex Med Física y Rehabilitación 2004; 16 (2): 37-40.

17. Turner A, Foster M, Johnson SE. Terapia Ocupacional y disfunción física. 5ª ed. España. El Sevier 2003.

18. Trombly CA . Terapia Ocupacional para enfermos incapacitados físicamente. La Prensa Médica Mexicana, 1990.

19. Hopkins HL. Smi th H D. Terapia Ocupacional. 8a edición España. Médica Panameri cana 2001; 431-450.

20. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003; 5 (1): 11-23.

21. Díaz ML, Arellano SME, del Valle CMG, Miranda DA , Rodríguez RG , Montero AA. Utilidad de la estimulación eléctrica neuromuscular posterior a la aplicación de toxina botulínica en niños con hemiparesia espástica. Rev Mex Med Física y Rehabilitación 2005; 17: 16-22.

22. Maya CM, Del Valle MG, Morales MG, Arellano ME. Utilidad de la toxina botulínica en la mejoría de la mano espástica en pacientes pediátricos con parálisis cerebral. Rev Mex Med Física y Rehabilitación 2004; 16: 18-22.

23. Weigl D, Arbel N, Katz K, Becker T, Bar- On E. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals. J Pediatr Orthop 2007; 16: 293-6.

24. Scholtes VA , Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG , Jongerius PH, et al. Eff ect of multilevel botulinum toxin A and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 2007; 36: 30-9.

25. Depedibi R, Ünlü E, Çevik ol A, Akk aya T, Cakci A, Cerekçi R, et al. Effi cacy of botulinum toxin type A in the management of children with cerebral palsy. NeuroRehabilitation 2008; 23: 159- 205.

26. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004; 19: 162-7.

27. Slawek J, Klimont L. Functional im provement in cerebral palsy patients treated with botulinum toxin injections- prelimi nary results. Eur J Neurol 2003; 10: 313-7.

28. Hawamdeh ZM, Ibrahim AI, Qudah AAL. Long term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. Eura Medicophysica 2007; 43: 311-8.

29. Nauman M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botilinum toxin type A following longterm use. Eur J Neurol 2006; 13: 35- 40.

30. Goldstein M. The treatment of cerebral palsy: what we know, what we don’t know. J Pediatr 2004; 145: S42-S46.